CYTK Cytokinetics (CYTK) Q1 FY26 earnings call
Cytokinetics delivered a strong quarter marked by the successful U.S. commercial launch of MYQORZO for oHCM, which exceeded initial expectations and demonstrated rapid patient uptake. The company also reported positive pivotal Phase III results for aficamten in nonobstructive HCM, positioning it as a potential treatment for the full spectrum of the disease. With European expansion underway and a robust pipeline, Cytokinetics is focused on disciplined execution and capital allocation to drive continued growth and address unmet patient needs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CYTK operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Prescribers MYQORZO | 275+In Q1, we saw strong demand with more than 275 unique HCPs prescribing MYQORZO with over 50% from the high-volume CMI writer segment.Source: earnings call transcript | 700+By the end of the quarter, more than 700 unique health care providers in the US have prescribed MYQORZO including approximately 300 physicians from the high-volume CMI writer segment.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.